| Literature DB >> 32724707 |
Lenine Angelo Alves Silva1, Enoch Brandão de Souza Meira2, Jefferson Curimbaba3, João A Pimenta3.
Abstract
Cardiac resynchronization therapy (CRT) improves symptoms and reduces morbidity and mortality in select heart failure patients but remains challenging to deploy widely because of difficult or unsuccessful coronary sinus (CS) access in up to 10% to 15% of patients. This report describes the radiological and anatomical aspects for improving CS catheterization and left ventricular (LV) lead positioning, focusing on the radioscopic and anatomical aspects, based on phlebography, to identify demanding cases in patients with dilated cardiomyopathy referred for CRT implantation. Anatomical and radiological aspects were explored in the anteroposterior, 30° left anterior oblique, and 30° right anterior oblique (RAO) views. In total, 117 phlebographies were performed in 39 consecutive procedures (one reintervention). Access to the CS was successful 37 times (94.9%). The most difficult cases were complicated by issues related to the altered spatial orientation of the CS ostium toward the tricuspid annular plane (TAP), which was best perceived in the 30° RAO projection and occurred in 37% of patients. One of two catheterization failures that occurred was caused by anomalous coronary venous drainage into the left atrium. Final LV lead positioning was successful in 36 (92.3%) of 39 procedures. More severe heart failure and worse LV ejection fraction did not translate into greater difficulty in LV lead implantation. As such, understanding anatomical and radiological relationships is the key to successful LV lead positioning. RAO projection can be particularly useful in the assessment of demanding CRT implant cases, especially when the CS ostium pointed to the TAP. Copyright:Entities:
Keywords: Cardiac resynchronization therapy; coronary sinus access; coronary sinus phlebography; left ventricular lead placement
Year: 2020 PMID: 32724707 PMCID: PMC7377645 DOI: 10.19102/icrm.2020.110703
Source DB: PubMed Journal: J Innov Card Rhythm Manag ISSN: 2156-3977
Patient Characteristics at Baseline, Procedure Success, and Time Intervals
| Characteristic | Total (n = 38) | Male (n = 21) | Female (n = 17) | p-value |
|---|---|---|---|---|
| Age, years | 0.243* | |||
| Mean ± SD (min–max) | 61 ± 10 (42–81) | 59 ± 11 (42–81) | 63 ± 9 (47–78) | |
| Median (IQR) | 61.5 (52–68) | 60 (50–69) | 63 (57–68) | |
| LVEF, % | 0.008* | |||
| Mean ± SD (min–max) | 31 ± 6 (17–38) | 28 ± 6 (17–38) | 34 ± 3 (25–38) | |
| Median (IQR) | 32 (28–34) | 30 (22–34) | 34 (32–36) | |
| NYHA class, mean ± SD | 3.4 ± 0.4 | 3.6 ± 0.4 | 3.2 ± 0.3 | 0.008* |
| Class III, n (%) | 27 (71.1) | 11 (52.4) | 16 (94.1) | |
| Class IV, n (%) | 11 (28.9) | 10 (47.6) | 1 (5.9) | |
| Etiology, n (%) | ||||
| Idiopathic | 6 (15.8) | 5 (23.8) | 1 (5.9) | |
| Ischemic | 11 (28.9) | 7 (33.3) | 4 (23.5) | |
| Chagasic | 5 (13.2) | 0 | 5 (29.4) | |
| Ischemic and chagasic | 1 (2.6) | 1 (4.8) | 0 | |
| Valvular | 4 (10.5) | 4 (19, 0) | 0 | |
| Hypertensive | 9 (23.7) | 3 (14.3) | 6 (35.3) | |
| Myocarditis | 1 (2.6) | 1 (4.8) | 0 | |
| ARVD | 1 (2.6) | 0 | 1 (5.9) | |
| Implanted device, n (%) | ||||
| CRT | 25 (65.8) | 12 (57.1) | 13 (76.5) | |
| CRT without atrial lead | 3 (7.9) | 3 (14.3) | 0 | |
| CRT-D | 8 (21.1) | 5 (23.8) | 3 (17.6) | |
| CRT-D without atrial lead | 2 (5.3) | 1 (4.8) | 1 (5.9) | |
| Procedure success rates, n (%)† | ||||
| Stable CS catheterization | 37 (94.9) | 21 (100.0) | 16 (88.9) | 0.387* |
| Final LV lead position | 36 (92.3) | 21 (100.0) | 15 (83.3) | 0.526* |
| Time interval, min, mean ± SD (min–max) | ||||
| From puncture to stable CS catheterization | 17 ± 22 (2–98) | 20 ± 28 (2–98) | 14 ± 9 (4–30) | 0.387* |
| For 37 successful catheterizations, median (IQR) | 8 (5–23) | 6 (4–26) | 12 (6–21) | |
| From stable CS catheterization to final LV | 30 ± 22 (10–107) | 32 ± 26 (10–107) | 26 ± 14 (10–62) | 0.950* |
| Lead position (for 36 successful implants), median (IQR) | 25 (17–31) | 21 (19–5) | 25 (14–31) | |
| From puncture to final LV lead position | 47 ± 29 (13–121) | 52 ± 35 (13–121) | 40 ± 18 (16–76) | 0.526* |
| For 36 successful implants, median (IQR) | 40 (25–55) | 37 (26–69) | 42 (24–53) | |
ARVD: arrhythmogenic right ventricular dysplasia; CS: coronary sinus; CRT-D: CRT with defibrillator backup; IQR: interquartile range; LV: left ventricular; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SD: standard deviation.
*Mann–Whitney U test.
†A total of 39 implantation procedures were included in the analyses, as one woman underwent two procedures.
Time Intervals as Function of LVEF (Median)
| Time Interval, min | LVEF ≤ 31% (n = 14) | LVEF > 31% (n = 23) | p-value |
|---|---|---|---|
| From puncture to stable CS catheterization* | 0.284*** | ||
| Mean ± SD (min–max) | 21 ± 24 (2–98) | 14 ± 20 (3–97) | |
| Median (IQR) | 19 (6–27) | 7 (4–17) | |
| From puncture to final LV lead position** | 0.860*** | ||
| Mean ± SD (min–max) | 48 ± 31 (13–121) | 46 ± 28 (17–115) | |
| Median (IQR) | 44 (28–57) | 36 (25–57) |
CS: coronary sinus; IQR: interquartile range; LV: left ventricular; LVEF: left ventricular ejection fraction; SD: standard deviation.
*Excluding one patient with anomalous drainage of the CS into the left atrium and the redo procedure (total = 37 patients).
**Excluding one patient with anomalous drainage of the CS into the left atrium and the redo procedure and one patient with unpreventable phrenic nerve stimulation (total = 36 patients).
***Mann–Whitney U test.
Time Intervals as Function of NYHA Class
| Time Interval, min | NYHA III (n = 26) | NYHA IV (n = 11) | p-value |
|---|---|---|---|
| From puncture to stable CS catheterization* | 0.612*** | ||
| Mean ± SD (min–max) | 16 ± 19 (3–98) | 19 ± 27 (2–97) | |
| Median (IQR) | 9 (6–23) | 6 (4–23) | |
| From puncture to final LV lead position** | 0.416*** | ||
| Mean ± SD (min–max) | 43 ± 24 (16–121) | 57 ± 38 (13–115) | |
| Median (IQR) | 36 (25–53) | 45 (30–107) |
Abbreviations: CS: coronary sinus; IQR: interquartile range; LV: left ventricular; NYHA: New York Heart Association; SD: standard deviation.
*Excluding one patient with anomalous drainage of the CS into the left atrium and the redo procedure (total = 37 patients).
**Excluding one patient with anomalous drainage of the CS into the left atrium and the redo procedure and one patient with unpreventable phrenic nerve stimulation (total = 36 patients).
***Mann–Whitney U test.
Time Intervals as Function of CS Ostium to the TAP
| Time interval, min | No CS to the TAP | Yes CS to the TAP | p-value |
|---|---|---|---|
| From puncture to stable CS catheterization* | |||
| Mean ± SD (min–max) | 11 ± 9 (3–33) | 27 ± 32 (2–98) | 0.180** |
| Median (IQR) | 8 (4–15) | 21 (5–28) | |
| From puncture to final LV lead position* | |||
| Mean ± SD (min–max) | 35 ± 17 (13–76) | 66 ± 34 (25–121) | 0.002** |
| Median (IQR) | 30 (22–49) | 53 (37–108) |
CS: coronary sinus; IQR: interquartile range; SD: standard deviation; TAP: tricuspid annular plane.
*Excluding one patient with anomalous drainage of the CS into the left atrium and the redo procedure and one patient with unpreventable phrenic nerve stimulation (total = 36 patients).
**Mann–Whitney U test.